Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.71 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.71 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747398 | 0.94 | HDAC1 (0.66) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL13290003 | 0.94 | HDAC1 (0.66) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL13290360 | 0.94 | HDAC1 (0.66) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL13289991 | 0.94 | HDAC1 (0.66) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL12890835 | 0.93 | HDAC1 (0.70) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL5018716 | 0.92 | HDAC1 (0.69) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL12890837 | 0.92 | HDAC1 (0.69) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL2747579 | 0.92 | HDAC1 (0.69) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL12890809 | 0.92 | HDAC1 (0.68) | HDAC1HDAC4HDAC8HDAC3HDAC7 | |
| SCHEMBL2749116 | 0.91 | HDAC1 (0.67) | HDAC1HDAC4HDAC8HDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893020-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7879795-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| US-6399629-B1 | PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY | MICROCIDE PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | HDAC1 352/4885HDAC4 337/4885HDAC8 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.